2.4 Drug information extraction
We evaluated 11 pulmonary vasodilators listed in Supplementary Table S1. The identification numbers of PAH patients treated with these drugs were extracted from the DRUG table. In this study, the PAH patients with concomitant use of PAH-specific vasodilators targeting the same biological pathways were excluded. We also evaluated supportive therapy for PAH, including oxygen therapy, anticoagulant therapy with warfarin or direct oral anticoagulant (DOAC), including apixaban, edoxaban, and rivaroxaban, and diuretic therapy with tolvaptan. Drugs reported in the DRUG table are categorized into ”suspected drug”, ”concomitant drug”, and ”interacting drug”. We employed drug information reported as ”suspected drug” and ”concomitant drug” for analyses in this study.